Patents Assigned to Calimmune Australia Pty Ltd
  • Modulatable switch for selection of donor modified cells
    Patent number: 10426798
    Abstract: The disclosed methods are generally directed to preventing, treating, suppressing, controlling or otherwise mitigating side effects of T-cell therapy, the T-cell therapy designed to accelerate immune reconstitution, induce a GVM effect, and/or target tumor cells.
    Type: Grant
    Filed: July 18, 2018
    Date of Patent: October 1, 2019
    Assignees: Calimmune, Inc., Calimmune Australia PTY LTD
    Inventors: Christopher Walter Alma, Jeffrey Bartlett, Louis Randall Breton, Geoffrey Phillip Symonds, Ming Yan
  • Methods for discriminating between HIV-1 and lentiviral vectors
    Patent number: 10240214
    Abstract: The present disclosure provides compositions (i.e., amplification primers and probes), methods, and kits that are particularly useful for detecting and/or quantifying nucleic acids present in a sample, such as those derived from HIV or a lentiviral vector.
    Type: Grant
    Filed: November 13, 2017
    Date of Patent: March 26, 2019
    Assignees: Calimmune, Inc., Calimmune Australia Pty Ltd, St. Vincent's Hospital Sydney Limited, Newsouth Innovations Pty Limited
    Inventors: Anthony Dominic Kelleher, Kazuo Suzuki, Geoffrey Phillip Symonds